Our products are based on a technology platform for the use of human cells as biocarriers of alarmins, endogenous molecules that are constitutively available and released through the company’s proprietary industrial process. Alarmins restore the normal wound’s micro environment: no available products currently have such cure potential.
KCPlus and FBPlus are two novel allogeneic epidermal and dermal substitute products for the treatment of chronic lower limb ulcers (CLLU). They are characterized by their contents in Alarmins Defensines and HMGB1, as markers of their role as biocarriers of proteins capable of promoting tissue regeneration and repair
KCPlus and FBPlus are able to restore the normal microenvironment of chronic wounds activating the healing process in a very efficient way. As of now, we are not aware of any products with this same mechanism of action and comparable efficacy